The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I study of SAR566658, an anti CA6-antibody drug conjugate (ADC), in patients (Pts) with CA6-positive advanced solid tumors (STs)(NCT01156870).
 
Carlos Alberto Gomez-Roca
Consulting or Advisory Role - Novartis; Sanofi
Travel, Accommodations, Expenses - Amgen; Roche
 
Valentina Boni
No Relationships to Disclose
 
Victor Moreno
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
John Charles Morris
Speakers' Bureau - Boehringer Ingelheim
Travel, Accommodations, Expenses - Amgen; VentiRx
 
Jean-Pierre Delord
No Relationships to Disclose
 
Emiliano Calvo
Consulting or Advisory Role - Astellas Pharma; GlaxoSmithKline; Lilly/ImClone; Nanobiotix; Novartis; Pfizer; Roche/Genentech
Speakers' Bureau - Novartis
Research Funding - Abbvie; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Janssen Oncology; Lilly; Merck; Millennium; Nektar; Novartis; OncoMed; Pfizer; PharmaMar; PsiOxus Therapeutics; Puma Biotechnology; Roche/Genentech; Sanofi; Spectrum Pharmaceuticals
Travel, Accommodations, Expenses - Lilly; Novartis; PsiOxus Therapeutics
Other Relationship - Pierre Fabre
 
Kyriakos P. Papadopoulos
Research Funding - Abbvie (Inst); ARMO BioSciences (Inst); ArQule (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); MedImmune (Inst); Novartis (Inst); Onyx (Inst); Regeneron (Inst); Sanofi (Inst)
 
Olivier Rixe
No Relationships to Disclose
 
Patrick Cohen
Employment - Sanofi
Stock and Other Ownership Interests - Sanofi
 
Alexia Tellier
Employment - Sanofi
 
Samira Ziti-Ljajic
Employment - Sanofi
 
Anthony W. Tolcher
Employment - START
Leadership - Symphony Evolution
Consulting or Advisory Role - Akebia Therapeutics; ArQule; Asana Biosciences; Astex Pharmaceuticals; Bayer Schering Pharma; Bind Therapeutics; Blend Therapeutics; Celator; Dicerna; Endocyte; Genmab; Heron; Janssen; Johnson & Johnson; Johnson & Johnson; Mersana; Merus; Nanobiotix; Pharmacyclics; Pierre Fabre; Proximagen; Symphony Evolution; Upsher-Smith; Valent Technologies
Research Funding - AbbVie (Inst); ArQule (Inst); Asana Biosciences (Inst); Astex Pharmaceuticals (Inst); Bayer (Inst); Cerulean Pharma (Inst); Dicerna (Inst); Endocyte (Inst); Gilead Sciences (Inst); Infinity Pharmaceuticals (Inst); Macrogenics (Inst); Pfizer (Inst); TaiRx, Inc. (Inst)